Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis.
Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG. Jairath V, et al. J Crohns Colitis. 2016 May;10(5):607-18. doi: 10.1093/ecco-jcc/jjw004. Epub 2016 Jan 7. J Crohns Colitis. 2016. PMID: 26746169 Free PMC article. Review.
Efficient Early Drug Development for Ulcerative Colitis.
Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. Khanna R, et al. Among authors: jairath v. Gastroenterology. 2016 May;150(5):1056-1060. doi: 10.1053/j.gastro.2016.03.013. Epub 2016 Mar 24. Gastroenterology. 2016. PMID: 27018491 No abstract available.
Treatment Targets in Ulcerative Colitis.
Khanna R, Jairath V. Khanna R, et al. Among authors: jairath v. Gastroenterology. 2016 Nov;151(5):1030-1032. doi: 10.1053/j.gastro.2016.09.028. Epub 2016 Sep 30. Gastroenterology. 2016. PMID: 27693330 No abstract available.
Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. Hindryckx P, et al. Among authors: jairath v. Aliment Pharmacol Ther. 2017 Mar;45(5):617-630. doi: 10.1111/apt.13913. Epub 2017 Jan 11. Aliment Pharmacol Ther. 2017. PMID: 28074618 Free PMC article. Review.
The safety of vedolizumab for the treatment of ulcerative colitis.
Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. Novak G, et al. Among authors: jairath v. Expert Opin Drug Saf. 2017 Apr;16(4):501-507. doi: 10.1080/14740338.2017.1300251. Epub 2017 Mar 5. Expert Opin Drug Saf. 2017. PMID: 28276855 Review.
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. D'Haens GR, et al. Among authors: jairath v. Aliment Pharmacol Ther. 2017 Aug;46(3):292-302. doi: 10.1111/apt.14164. Epub 2017 Jun 1. Aliment Pharmacol Ther. 2017. PMID: 28568974 Clinical Trial.
467 results